Eli Lilly (LLY) Wins FDA Breakthrough Tag For Olomorasib, Is The Stock Still Cheap?

Eli Lilly (LLY) stock is back in focus after the FDA granted Breakthrough Therapy designation to its investigational drug olomorasib for KRAS G12C-mutant advanced pancreatic cancer, highlighting an expanding oncology effort. See our latest analysis for Eli Lilly. Eli Lilly’s share price has eased recently, with a 7 day share price return down 8.60% and a 30 day share price return down 8.09%. This is even though the 1 year total shareholder return sits at 46.69% and the 5 year total...